Second Time's The Charm: Novartis' New Bid Lures Chiron
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron's vaccines unit will operate as a separate division while its biopharmaceuticals unit will merge with Novartis' pharmaceutical business.